Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Edward B Rubenstein

Showing results (1-10 of 14) with videos related to

Pageof 2
Sort By:
Clinical Advances in Hematology & Oncology : H&O|September 16, 2005
Palonosetron: a unique 5-HT3 receptor antagonist indicated for the prevention of acute and delayed chemotherapy-induced nausea and vomitingEdward B Rubenstein
Supportive Cancer Therapy|July 17, 2008
Role of prophylactic quinolones in reducing febrile neutropenia in patients undergoing myelosuppressive chemotherapyG Kesava Reddy, Edward B Rubenstein
Seminars in Oncology Nursing|March 25, 2004
Evidence-based guidelines for managing mucositisDeborah B McGuire, Edward B Rubenstein, Douglas E Peterson
Cancer Journal (Sudbury, Mass.)|October 13, 2006
New approaches to chemotherapy-induced nausea and vomiting: from neuropharmacology to clinical investigationsEdward B Rubenstein, Barbara S Slusher, Camilo Rojas, et al.
Cancer|June 5, 2003
Pharmacoeconomic analysis of oprelvekin (recombinant human interleukin-11) for secondary prophylaxis of thrombocytopenia in solid tumor patients receiving chemotherapyScott B Cantor, Linda S Elting, David V Hudson, et al.
Cancer|July 25, 2003
Measuring chemotherapy-induced nausea and emesisCharles G Martin, Edward B Rubenstein, Linda S Elting, et al.
Cancer|September 26, 2003
The burdens of cancer therapy. Clinical and economic outcomes of chemotherapy-induced mucositisLinda S Elting, Catherine Cooksley, Mark Chambers, et al.
European Journal of Pharmacology|October 20, 2009
Palonosetron triggers 5-HT(3) receptor internalization and causes prolonged inhibition of receptor functionCamilo Rojas, Ajit G Thomas, Jesse Alt, et al.
Cancer|May 13, 2004
Incidence of chemotherapy-induced nausea and emesis after modern antiemeticsSteven M Grunberg, Robert R Deuson, Panagiotis Mavros, et al.
Cancer|July 13, 2002
The Bleeding Risk Index: a clinical prediction rule to guide the prophylactic use of platelet transfusions in patients with lymphoma or solid tumorsLinda S Elting, Charles G Martin, Danna J Kurtin, et al.
Pageof 2

Showing results (1-10 of 14) with videos related to

Sort By:
Pageof 2
Clinical Advances in Hematology & Oncology : H&O|September 16, 2005
Palonosetron: a unique 5-HT3 receptor antagonist indicated for the prevention of acute and delayed chemotherapy-induced nausea and vomitingEdward B Rubenstein
Supportive Cancer Therapy|July 17, 2008
Role of prophylactic quinolones in reducing febrile neutropenia in patients undergoing myelosuppressive chemotherapyG Kesava Reddy, Edward B Rubenstein
Seminars in Oncology Nursing|March 25, 2004
Evidence-based guidelines for managing mucositisDeborah B McGuire, Edward B Rubenstein, Douglas E Peterson
Cancer Journal (Sudbury, Mass.)|October 13, 2006
New approaches to chemotherapy-induced nausea and vomiting: from neuropharmacology to clinical investigationsEdward B Rubenstein, Barbara S Slusher, Camilo Rojas, et al.
Cancer|June 5, 2003
Pharmacoeconomic analysis of oprelvekin (recombinant human interleukin-11) for secondary prophylaxis of thrombocytopenia in solid tumor patients receiving chemotherapyScott B Cantor, Linda S Elting, David V Hudson, et al.
Cancer|July 25, 2003
Measuring chemotherapy-induced nausea and emesisCharles G Martin, Edward B Rubenstein, Linda S Elting, et al.
Cancer|September 26, 2003
The burdens of cancer therapy. Clinical and economic outcomes of chemotherapy-induced mucositisLinda S Elting, Catherine Cooksley, Mark Chambers, et al.
European Journal of Pharmacology|October 20, 2009
Palonosetron triggers 5-HT(3) receptor internalization and causes prolonged inhibition of receptor functionCamilo Rojas, Ajit G Thomas, Jesse Alt, et al.
Cancer|May 13, 2004
Incidence of chemotherapy-induced nausea and emesis after modern antiemeticsSteven M Grunberg, Robert R Deuson, Panagiotis Mavros, et al.
Cancer|July 13, 2002
The Bleeding Risk Index: a clinical prediction rule to guide the prophylactic use of platelet transfusions in patients with lymphoma or solid tumorsLinda S Elting, Charles G Martin, Danna J Kurtin, et al.
Pageof 2